

To: [5.1.2e] [5.1.2e] [5.1.2e] ([5.1.2e]) ([5.1.2e]) ([5.1.2e]) ([5.1.2e])@minvws.nl]
From: [5.1.2e] [5.1.2e]
Sent: Mon 11/23/2020 10:12:13 PM
Subject: RE: AstraZeneca/Oxford AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19
Received: Mon 11/23/2020 10:12:16 PM

[5.1.2i]

Zo iets?

[5.1.2e]

From: [5.1.2e] [5.1.2e] [5.1.2e] ([5.1.2e]) ([5.1.2e]) ([5.1.2e]) ([5.1.2e])@minvws.nl>
Sent: maandag 23 november 2020 18:57
To: [5.1.2e] [5.1.2e] <[5.1.2e]@rivm.nl>
Subject: RE: AstraZeneca/Oxford AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19

Overigens wil minister dat er snel (rechtstreeks) contact is over leveringsplannen Pfizer en AZ, daar refereert [5.1.2e] aan in haar mail
 Groet [5.1.2e]

Van: [5.1.2e] [5.1.2e] [5.1.2e] ([5.1.2e])
Verzonden: maandag 23 november 2020 18:50
Aan: [5.1.2e] [5.1.2e] <[5.1.2e]@rivm.nl>
CC: [5.1.2e] [5.1.2e] ([5.1.2e]) <[5.1.2e]@minvws.nl>; [5.1.2e] [5.1.2e] ([5.1.2e]) <[5.1.2e]@minvws.nl>; [5.1.2e] [5.1.2e] ([5.1.2e]) <[5.1.2e]@minvws.nl>; [5.1.2e] [5.1.2e] ([5.1.2e]) <[5.1.2e]@minvws.nl>; [5.1.2e] [5.1.2e] ([5.1.2e]) <[5.1.2e]@minvws.nl>
Onderwerp: FW: AstraZeneca/Oxford AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19

Ha [5.1.2e] kun jij ons helpen met korte appreciatie/reactie hierop? En dan kunnen we in de richting van AZ ook even mooi antwoord sturen
 Groet [5.1.2e]

Van: [5.1.2e] [5.1.2e] ([5.1.2e]) <[5.1.2e]@minvws.nl>
Verzonden: maandag 23 november 2020 13:38
Aan: [5.1.2e] [5.1.2e] [5.1.2e] ([5.1.2e]) <[5.1.2e]@minvws.nl>; [5.1.2e] [5.1.2e] ([5.1.2e]) <[5.1.2e]@minvws.nl>; [5.1.2e] [5.1.2e] ([5.1.2e]) <[5.1.2e]@minvws.nl>; [5.1.2e] [5.1.2e] ([5.1.2e]) <[5.1.2e]@minvws.nl>; [5.1.2e] [5.1.2e] ([5.1.2e]) <[5.1.2e]@minvws.nl>
CC: [5.1.2e] [5.1.2e] ([5.1.2e]) <[5.1.2e]@minvws.nl>
Onderwerp: FW: AstraZeneca/Oxford AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19

Hi allen,

Nav mijn vorige mail over verzoek van VWS, stuur ik jullie hierbij ook deze brief van AstraZeneca toe.

Mooie opening voor een gesprek lijkt me..

Groet,

[5.1.2e]

We would like to thank you for your continued partnership and would welcome the opportunity to speak with you to discuss today's announcement in greater detail.

Best regards,

5.1.2e

AstraZeneca Netherlands

AstraZeneca

M: 5.1.2e

5.1.2e [@astrazeneca.com](mailto:5.1.2e@astrazeneca.com)

5.1.2e

5.1.2e [@astrazeneca.com](mailto:5.1.2e@astrazeneca.com)

AstraZeneca UK Limited is a company incorporated in England and Wales with registered number:03674842 and its registered office at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA.

This e-mail and its attachments are intended for the above named recipient only and may contain confidential and privileged information. If they have come to you in error, you must not copy or show them to anyone; instead, please reply to this e-mail, highlighting the error to the sender and then immediately delete the message. For information about how AstraZeneca UK Limited and its affiliates may process information, personal data and monitor communications, please see our privacy notice at www.astrazeneca.com

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.
www.rivm.nl De zorg voor morgen begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.

www.rivm.nl/en Committed to health and sustainability